Last $43.67 USD
Change Today -0.09 / -0.21%
Volume 3.2M
As of 12:29 PM 05/21/13 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$43.82
Previous Close
$43.76
Day High
$44.44
Day Low
$43.45
52 Week High
05/15/13 - $45.59
52 Week Low
11/15/12 - $30.64
Market Cap
71.7B
Average Volume 10 Days
13.5M
EPS TTM
$1.69
Shares Outstanding
1.6B
EX-Date
04/3/13
P/E TM
25.8x
Dividend
$1.40
Dividend Yield
3.16%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BMY)

bristol-myers squibb co (BMY) Latest News

More News

bristol-myers squibb co (BMY) Related Businessweek News

View More BusinessWeek News

bristol-myers squibb co (BMY) Details

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company’s products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

28,000 Employees
Last Reported Date: 02/15/13
Founded in 1887

bristol-myers squibb co (BMY) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $1.6M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $868.6K
President of Research & Development, Chief Sc...
Total Annual Compensation: $1.1M
Executive Vice President of Commercial Operat...
Total Annual Compensation: $868.6K
General Counsel and Corporate Secretary
Total Annual Compensation: $768.7K
Compensation as of Fiscal Year 2012.

bristol-myers squibb co (BMY) Key Developments

Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb

Adaptive Biotechnologies announced that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response. The immunoSEQ assay uses high throughput next-generation sequencing to characterize the repertoire of T and B cell receptors. Application of this technology is being explored in cells of cancer patients, to assess the impact of treatments on the immune system and evaluated as a tool to identify patient populations who might be more likely to respond to targeted therapies based on their immune status.

Bristol-Myers Squibb Company Presents at UBS Global Healthcare Conference, May-21-2013 08:30 AM

Bristol-Myers Squibb Company Presents at UBS Global Healthcare Conference, May-21-2013 08:30 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Charles A. Bancroft, Chief Financial Officer and Executive Vice President.

Bristol-Myers Squibb Company - Shareholder/Analyst Call

Annual Shareholder Meeting

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $43.67 USD -0.09

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $46.68 USD +0.42
Amgen Inc $104.06 USD +1.88
Eli Lilly & Co $54.95 USD -0.07
Novo Nordisk A/S kr989.50 DKK -5.50
Takeda Pharmaceutical Co Ltd ¥4,945 JPY -5.00
View Industry Companies
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 49.4x
Price/Sales 4.4x
Price/Book 5.2x
Price/Cash Flow 48.4x
TEV/Sales 3.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.